Smart Relief Alliance 360: BIEL + Viant + VLMS
AI-Powered Pain Therapy. Open-Market Equity. Wellness Expansion. Institutional Tailwinds.
Vision
BioElectronics Corporation (BIEL) is more than a pain therapy company—it’s a scalable, AI-powered health platform. With FDA-cleared PEMF wearables like ActiPatch, RecoveryRx, and RecoveryRx Veterinary, the company reaches consumers, clinicians, and pet owners across the globe.
The Smart Relief Alliance—composed of BIEL, Viant Medical, VLMS Healthcare, and visionary leaders Keith Nalepka and Dr. Sree Koneru—delivers technology, infrastructure, and commercialization in lockstep. The result: a precision-built pathway to viral growth and equity-powered prosperity.
Netflix Economics, BIEL Edition
BIEL’s business model mirrors early Netflix dynamics—with a twist:
Similar Pricing: ActiPatch costs ~$35, similar to a monthly Netflix subscription—but delivers hundreds of hours of pain relief
Far Greater Reach: BIEL targets every human with pain... and their pets (via RecoveryRx Veterinary)
Higher Margins: No studio overhead—just lean hardware sales and scalable software
Netflix rose 325,000% since IPO. With policy tailwinds, open-market access, and device-based profit, BIEL may follow a similar arc—with broader healthcare impact.
Revenue Channels
Device Sales: $50–$100 per unit
Subscriptions: $5–$10/month for dashboard, coaching, and analytics
Data Licensing: Pharma and research access to anonymized health data
Wellness Use: Migraines, menstrual pain, RLS, neuropathy, BPH—no added FDA approvals necessary
Veterinary Market: Disrupts Assisi Loop with superior lifespan and value
Policy Tailwind: NOPAIN for Veterans Act
Federal legislation introduces powerful institutional momentum:
Inclusion on VA formularies for ActiPatch and RecoveryRx
Streamlined reimbursement for millions of veterans
Validates Viant and VLMS as systemic healthcare leaders
Drives clinical volume, credibility, and share price acceleration
This isn’t just access—it’s government-backed demand. And it doubles as a revenue and equity multiplier.
RecoveryRx Veterinary: Hidden Gem
300+ Assisi Loop units sell per month on Amazon at $329 with 1/20 the battery life of RecoveryRx Veterinary - Equivalent to $6,000/year in value—but consumers accept the price
RecoveryRx offers better performance at a fraction of the cost—creating opportunity for bundles, ecommerce growth, and widespread clinic adoption.
PPS Milestones: Mapped for Momentum
1️⃣ $0.0004–$0.0005 – Technical breakout (Golden Cross + Blue Sky)
2️⃣ $0.003 – 3,000% surge from U.S. distributor news and media buzz
3️⃣ $0.01 – A $400K quarter or $1.5M annual signal
4️⃣ $0.04 – $10M profit matches Bitcoin-era multiples
5️⃣ $0.10 – 100,000% increase with $25M profit and tax-free gains
With ~10B float and ~15B locked long-term, structural scarcity accelerates PPS when demand hits.
Execution Team
BIEL: IP, FDA clearance, wellness market footprint
Viant Medical: App platform, device design, scalable manufacturing
VLMS Healthcare: AI marketing, billing, coding, hospital partnerships
Keith Nalepka: Distribution expert, retail sales catalyst
Dr. Sree Koneru: R&D velocity, QA, and regulatory execution
Summary
Execution = investment. Ownership = upside.
A smartphone-connected AI health app co-developed by BIEL and Viant Medical could tap into a booming market
Every device sold drives relief. Every milestone hit drives wealth.
The Smart Relief Alliance isn’t hypothetical—it’s activated. From FDA clearance to AI precision, pet wellness to VA prescribing, from Wall Street buzz to Reddit virality—this platform checks every box.
This is BIEL’s breakout moment. Just like Netflix—but built on pain relief, not programming.
AI-Powered Pain Therapy. Open-Market Equity. Wellness Expansion. Institutional Tailwinds.
Vision
BioElectronics Corporation (BIEL) is more than a pain therapy company—it’s a scalable, AI-powered health platform. With FDA-cleared PEMF wearables like ActiPatch, RecoveryRx, and RecoveryRx Veterinary, the company reaches consumers, clinicians, and pet owners across the globe.
The Smart Relief Alliance—composed of BIEL, Viant Medical, VLMS Healthcare, and visionary leaders Keith Nalepka and Dr. Sree Koneru—delivers technology, infrastructure, and commercialization in lockstep. The result: a precision-built pathway to viral growth and equity-powered prosperity.
Netflix Economics, BIEL Edition
BIEL’s business model mirrors early Netflix dynamics—with a twist:
Similar Pricing: ActiPatch costs ~$35, similar to a monthly Netflix subscription—but delivers hundreds of hours of pain relief
Far Greater Reach: BIEL targets every human with pain... and their pets (via RecoveryRx Veterinary)
Higher Margins: No studio overhead—just lean hardware sales and scalable software
Netflix rose 325,000% since IPO. With policy tailwinds, open-market access, and device-based profit, BIEL may follow a similar arc—with broader healthcare impact.
Revenue Channels
Device Sales: $50–$100 per unit
Subscriptions: $5–$10/month for dashboard, coaching, and analytics
Data Licensing: Pharma and research access to anonymized health data
Wellness Use: Migraines, menstrual pain, RLS, neuropathy, BPH—no added FDA approvals necessary
Veterinary Market: Disrupts Assisi Loop with superior lifespan and value
Policy Tailwind: NOPAIN for Veterans Act
Federal legislation introduces powerful institutional momentum:
Inclusion on VA formularies for ActiPatch and RecoveryRx
Streamlined reimbursement for millions of veterans
Validates Viant and VLMS as systemic healthcare leaders
Drives clinical volume, credibility, and share price acceleration
This isn’t just access—it’s government-backed demand. And it doubles as a revenue and equity multiplier.
RecoveryRx Veterinary: Hidden Gem
300+ Assisi Loop units sell per month on Amazon at $329 with 1/20 the battery life of RecoveryRx Veterinary - Equivalent to $6,000/year in value—but consumers accept the price
RecoveryRx offers better performance at a fraction of the cost—creating opportunity for bundles, ecommerce growth, and widespread clinic adoption.
PPS Milestones: Mapped for Momentum
1️⃣ $0.0004–$0.0005 – Technical breakout (Golden Cross + Blue Sky)
2️⃣ $0.003 – 3,000% surge from U.S. distributor news and media buzz
3️⃣ $0.01 – A $400K quarter or $1.5M annual signal
4️⃣ $0.04 – $10M profit matches Bitcoin-era multiples
5️⃣ $0.10 – 100,000% increase with $25M profit and tax-free gains
With ~10B float and ~15B locked long-term, structural scarcity accelerates PPS when demand hits.
Execution Team
BIEL: IP, FDA clearance, wellness market footprint
Viant Medical: App platform, device design, scalable manufacturing
VLMS Healthcare: AI marketing, billing, coding, hospital partnerships
Keith Nalepka: Distribution expert, retail sales catalyst
Dr. Sree Koneru: R&D velocity, QA, and regulatory execution
Summary
Execution = investment. Ownership = upside.
A smartphone-connected AI health app co-developed by BIEL and Viant Medical could tap into a booming market
Every device sold drives relief. Every milestone hit drives wealth.
The Smart Relief Alliance isn’t hypothetical—it’s activated. From FDA clearance to AI precision, pet wellness to VA prescribing, from Wall Street buzz to Reddit virality—this platform checks every box.
This is BIEL’s breakout moment. Just like Netflix—but built on pain relief, not programming.
